Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals Digital

Home Control International Partners with Articura on Localized Healthcare AI Infrastructure in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Sino Biopharmaceutical and Tempo Scan Form JV to Commercialize Innovative Drugs in Indonesia

Fineline Cube Jul 27, 2026
Company Deals

Nona Biosciences Partners with Medical University of Vienna on Infectious Disease Antibody Research Using Proprietary H2L2 Harbour Mice Platform

Fineline Cube Jul 24, 2026
Company Deals

Pakistan-China Pharma Pact: $440M in Agreements Positions Pakistan as Regional Medicines Hub

Fineline Cube Jul 24, 2026
Company Deals

Summit Therapeutics and Arcus Biosciences Launch Global Trial of Ivonescimab-Casdatifan Combination for Renal Cell Carcinoma

Fineline Cube Jul 23, 2026
Policy / Regulatory

Trump Announces Phased Tariff Policy on Generic Drug Imports to Incentivize U.S. Manufacturing Reshoring

Fineline Cube Jul 23, 2026
Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Fineline Cube Jul 28, 2026
Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Fineline Cube Jul 28, 2026
Company Deals

Salus Biotech Partners with Xi’an Jiaotong University for Single-Cell Omics Innovation

Fineline Cube Jul 12, 2024

Salus Biotech, a Shenzhen-based biotechnology company, has entered into a strategic partnership with the Single-cell...

Company Drug

KeChow Pharma’s Keluping, First NRAS Mutant Melanoma Therapy, Hits the Market

Fineline Cube Jul 12, 2024

Shanghai-based KeChow Pharma has announced the official market launch of its groundbreaking drug, Keluping (tunlametinib),...

Company Deals

Biokin Pharmaceutical Co., Ltd Eyes Secondary Listing on HKEX, Co-Sponsored by Goldman Sachs and Others

Fineline Cube Jul 11, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a company listed on the Shanghai Stock Exchange’s...

Company Deals

Allist Pharmaceuticals Faces Arbitration Over Promotion Agreement for Furmonertinib

Fineline Cube Jul 11, 2024

Allist Pharmaceuticals Co., Ltd, a Shanghai-based biopharmaceutical company, has announced that it has received a...

Company

Bayer Restructures China Business into Five Sectors and Six Departments

Fineline Cube Jul 11, 2024

Bayer (ETR: BAYN), the German pharmaceutical and life sciences giant, has announced a strategic restructuring...

Company Deals Digital

Digital Health China Partners with Huawei to Launch Intelligent Multimodal Big Data System for Healthcare

Fineline Cube Jul 11, 2024

Digital Health China Technologies Co., Ltd., a leading cloud-based healthcare service provider based in China,...

Company

Pfizer and AbbVie Announce Leadership Changes in Global R&D Divisions

Fineline Cube Jul 11, 2024

In significant executive reshuffling, Pfizer Inc. (NYSE: PFE) and AbbVie (NYSE: ABBV) have both announced...

Company Deals

Pfizer Collaborates with Evotec for Drug Candidates in Metabolic and Infectious Diseases

Fineline Cube Jul 11, 2024

Pfizer Inc. (NYSE: PFE) has entered into a multi-year collaboration with Germany-based biotechnology company Evotec...

Company Deals

Novo Nordisk Partners with Indonesia’s Bio Farma to Boost Asia-Pacific Diabetes Drug Production

Fineline Cube Jul 11, 2024

Novo Nordisk (NYSE: NVO; CPH: NOVO-B), the Danish pharmaceutical giant specializing in diabetes care, is...

Company

Abbisko Therapeutics Forecasts Profits and Revenue Boost in H1 2024 on Merck Deal

Fineline Cube Jul 11, 2024

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has released a positive financial...

Company

Junshi Biosciences’ Subsidiary Secures EU GMP Certification, Strengthening Loqtorzi’s Market Prospects

Fineline Cube Jul 11, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Deals

AFT Pharmaceuticals Partners with Hainan Haiyao for Distribution of Crystaderm Cream in China

Fineline Cube Jul 10, 2024

AFT Pharmaceuticals (JSE: AFT, ASX: ASX), a company based in New Zealand, has announced an...

Company Drug

Amgen Halts Development of Claudin 6-Targeting BiTE Immune Therapy AMG 794

Fineline Cube Jul 10, 2024

Amgen Inc. (NASDAQ: AMGN), a leading biopharmaceutical company based in the U.S., has decided to...

Company Drug

Kymera Therapeutics’ Stock Soars on Sanofi’s Plans to Expand KT-474 Clinical Trials

Fineline Cube Jul 10, 2024

Kymera Therapeutics Inc. (NASDAQ: KYMR), a biopharmaceutical company based in the U.S., has announced that...

Company Deals

BGI Genomics’ Subsidiary Inks 3-Year Noninvasive Prenatal Test Agreement with Heilongjiang Province

Fineline Cube Jul 10, 2024

BGI Genomics Co., Ltd (SHE: 300676), a leading genomics company based in China, has announced...

Company Drug

Shanghai Vitalgen BioPharma Launches Phase I/II Gene Therapy Trial for Parkinson’s Disease

Fineline Cube Jul 10, 2024

Shanghai Vitalgen BioPharma Co., Ltd, a biopharmaceutical company based in China, has initiated a Phase...

Company Drug

Kintor Pharmaceutical Launches Global Cosmetic Line with Hair Loss Treatment Pyrilutamide

Fineline Cube Jul 10, 2024

Kintor Pharmaceutical Ltd (HKG: 9939), a biopharmaceutical company based in China, has announced the global...

Company Drug

Suzhou Sanegene Bio Receives NMPA Approval for Clinical Trial of Antihypertensive siRNA Drug

Fineline Cube Jul 10, 2024

Suzhou Sanegene Bio Inc., a leading RNAi specialist with research and development centers in both...

Company Drug

Shanghai Junshi Biosciences’ HDAC Inhibitor JS125 Clinical Trial Application Accepted by NMPA

Fineline Cube Jul 10, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has announced that the National Medical...

Company Drug

Johnson & Johnson’s Opsumit Faces Generic Competition with Qilu Pharmaceutical’s Entry

Fineline Cube Jul 10, 2024

Johnson & Johnson (J&J, NYSE: JNJ)’s pulmonary hypertension treatment, Opsumit (macitentan), is set to encounter...

Posts pagination

1 … 366 367 368 … 700

Recent updates

  • InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial
  • Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China
  • Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials
  • GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study
  • Sichuan Kelun’s Dual-Payload ADC SKB565 Receives NMPA Clearance for Advanced Solid Tumor Clinical Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

InnoCare’s TYK2 Inhibitor Fadeucravacitinib Hits Primary Endpoint in Phase III Psoriasis Trial

Company Drug

Hengrui’s Mineralocorticoid Receptor Antagonist HRS-1780 Advances to Phase 2/3 for Resistant Hypertension in China

Company Drug

Bio-Sincerity’s First-in-Class Epigenetic Inhibitor BIOS0635-048 Receives NMPA Clearance for Advanced Solid Tumor Trials

Company Drug

GSK’s Dovato Demonstrates Non-Inferior Efficacy to Biktarvy in Phase IIIb VOGUE HIV Study

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.